DURHAM, N.C., Sept. 8, 2010 –(HSMN NewsFeed) — Curaxis Pharmaceutical Corp (OTCBB:CURX ) today announced an update on the Company’s clinical development plans for Memryte, its candidate to treat mild-to-moderate Alzheimer’s disease. The cumulative cos…
Biopharmaceuticals, Neurology
Curaxis Pharmaceutical, Memryte, Alzheimer’s disease

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Curaxis Clinical Corp CEO Patrick S. Smith Announces Plans for Further Clinical Trials for Alzheimer’s Treatment”
Leave a Comment